These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35450353)

  • 1. Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.
    Chen Y; Singh R; Lin N; Taylor V; Masuda ES; Payan DG
    ACS Med Chem Lett; 2022 Apr; 13(4):714-719. PubMed ID: 35450353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.
    Chen Y; Tso K; Heckrodt TJ; Li H; Yen R; Lin N; Singh R; Taylor V; Masuda ES; Park G; Payan DG
    Bioorg Med Chem Lett; 2022 Oct; 73():128900. PubMed ID: 35863718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
    Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
    McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
    Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
    Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Fischmann T; Gibeau C; Kleinschek MA; Leccese E; Lesburg C; Maclean JK; Moy LY; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Steinhuebel D; Yang R
    ACS Med Chem Lett; 2015 Jun; 6(6):683-8. PubMed ID: 26101574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
    Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
    J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
    Li X
    Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kinase activity of IL-1 receptor-associated kinase 4 is required for interleukin-1 receptor/toll-like receptor-induced TAK1-dependent NFkappaB activation.
    Fraczek J; Kim TW; Xiao H; Yao J; Wen Q; Li Y; Casanova JL; Pryjma J; Li X
    J Biol Chem; 2008 Nov; 283(46):31697-705. PubMed ID: 18794297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
    Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
    J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors.
    Seganish WM; Fischmann TO; Sherborne B; Matasi J; Lavey B; McElroy WT; Tulshian D; Tata J; Sondey C; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
    ACS Med Chem Lett; 2015 Aug; 6(8):942-7. PubMed ID: 26288698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
    Genung NE; Guckian KM
    Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of IRAK4 inhibitor activity prediction model based on machine learning.
    Zhao Y; Wan Q; He X
    Mol Divers; 2024 Jul; ():. PubMed ID: 38970641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.
    Wang H; Zhou H; Zhang Q; Poulsen KL; Taylor V; McMullen MR; Czarnecki D; Dasarathy D; Yu M; Liao Y; Allende DS; Chen X; Hong L; Zhao J; Yang J; Nagy LE; Li X
    J Hepatol; 2020 Dec; 73(6):1470-1481. PubMed ID: 32682051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
    McElroy WT; Tan Z; Ho G; Paliwal S; Li G; Seganish WM; Tulshian D; Tata J; Fischmann TO; Sondey C; Bian H; Bober L; Jackson J; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
    ACS Med Chem Lett; 2015 Jun; 6(6):677-82. PubMed ID: 26101573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity.
    Rajapaksa NS; Gobbi A; Drobnick J; Do S; Kolesnikov A; Liang J; Chen Y; Sujatha-Bhaskar S; Huang Z; Brightbill H; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR; Bryan MC
    ACS Med Chem Lett; 2020 Mar; 11(3):327-333. PubMed ID: 32184965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
    Lavazais S; Jargosch M; Dupont S; Labéguère F; Menet C; Jagerschmidt C; Ohm F; Kupcsik L; Parent I; Cottereaux C; Marsais F; Oste L; Van de Water A; Christophe T; De Vos S; Fallon P; Lauffer F; Clément-Lacroix P; Eyerich K; Brys R
    Sci Transl Med; 2023 Feb; 15(683):eabj3289. PubMed ID: 36791209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
    Bhujbal SP; He W; Hah JM
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate.
    Chen Y; Li H; Yen R; Heckrodt TJ; McMurtrie D; Singh R; Taylor V; Masuda ES; Park G; Payan DG
    ACS Med Chem Lett; 2022 Nov; 13(11):1805-1811. PubMed ID: 36385926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.